The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). 2019;394(10204):1145–1158.
   PubMed Web of Science ®Google Scholar
• Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–117.
   PubMed Web of Science ®Google Scholar
• Anstee QM, Reeves HL, Kotsiliti E, et al. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16(7):411–428.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet (London, England). 2018;391(10127):1301–1314.
   PubMed Web of Science ®Google Scholar
• Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–855.
   PubMed Web of Science ®Google Scholar
• Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;48(6):598–609.
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604.
   PubMed Web of Science ®Google Scholar
• Monto A, Wright TL. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol. 2001;28(5):441–449.
   PubMed Web of Science ®Google Scholar
• Lodato F, Mazzella G, Festi D, et al. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol. 2006;12(45):7239–7249.
   PubMed Web of Science ®Google Scholar
• Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7(12):1394–1403.
   PubMed Web of Science ®Google Scholar
• Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC – challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 2018;15(9):577–586.
   PubMed Web of Science ®Google Scholar
• Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol. 2018;52(Pt 1):56–73.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu X, Long G, et al. The clinical value of total plasma cell-free DNA in hepatitis B virus-related hepatocellular carcinoma. Ann Transl Med. 2019;7(22):650.
   PubMed Web of Science ®Google Scholar
• Cai J, Chen L, Zhang Z, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019;68(12):2195–2205.
   PubMed Web of Science ®Google Scholar
• Yan L, Chen Y, Zhou J, et al. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma. Int J Infect Dis. 2018;67:92–97.
   PubMed Web of Science ®Google Scholar
• Chen K, Zhang H, Zhang L-N, et al. Value of circulating cell-free DNA in diagnosis of hepatocellular carcinoma. World J Gastoenterol. 2013;19(20):3143–3149.
   PubMed Web of Science ®Google Scholar
• Chae YK, Oh MS. Detection of minimal residual disease using ctDNA in lung cancer: current evidence and future directions. J Thorac Oncol. 2019;14(1):16–24.
   PubMed Web of Science ®Google Scholar
• Xu R-H, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017;16(11):1155–1161.
   PubMed Web of Science ®Google Scholar
• Liu H, Xu Y, Xiang J, et al. Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer. Clin Cancer Res. 2017;23(2):478–488.
   PubMed Web of Science ®Google Scholar
• An Y, Guan Y, Xu Y, et al. The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma. Am J Transl Res. 2019;11:6462–6474.
   PubMed Web of Science ®Google Scholar
• Mann J, Reeves HL, Feldstein AE. Liquid biopsy for liver diseases. Gut. 2018;67(12):2204–2212.
   PubMed Web of Science ®Google Scholar
• Yang JD, Liu MC, Kisiel JB. Circulating tumor DNA and hepatocellular carcinoma. Semin Liver Dis. 2019;39(4):452–462.
   PubMed Web of Science ®Google Scholar
• Ye Q, Ling S, Zheng S, et al. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019;18(1):114.
   PubMedGoogle Scholar
• Li J, Han X, Yu X, et al. Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. J Exp Clin Cancer Res. 2018;37(1):213.
   PubMedGoogle Scholar
• Okajima W, Komatsu S, Ichikawa D, et al. Liquid biopsy in patients with hepatocellular carcinoma: circulating tumor cells and cell-free nucleic acids. World J Gastroenterol. 2017;23(31):5650–5668.
   PubMed Web of Science ®Google Scholar
• Choudhury AD, Werner L, Francini E, et al. Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018;3(21):e122109.
   PubMed Web of Science ®Google Scholar
• Mezzalira S, De Mattia E, Guardascione M, et al. Circulating-free DNA analysis in hepatocellular carcinoma: a promising strategy to improve patients' management and therapy outcomes. Int J Mol Sci. 2019;20(21):5498.
   Web of Science ®Google Scholar
• Pezzuto F, Buonaguro L, Buonaguro FM, et al. The role of circulating free DNA and MicroRNA in non-invasive diagnosis of HBV- and HCV-related hepatocellular carcinoma. Int J Mol Sci. 2018;19:1007.
   Web of Science ®Google Scholar
• Shen S, Lin Y, Yuan X, et al. Biomarker MicroRNAs for diagnosis, prognosis and treatment of hepatocellular carcinoma: a functional survey and comparison. Sci Rep. 2016;6:38311.
   PubMed Web of Science ®Google Scholar